Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563134 | 0.83 | MAPT (0.35) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5668902 | 0.82 | CACNA1G (0.44) | MAPTCYP1A2CYP2C19HTTCACNA1G | |
| SCHEMBL5670152 | 0.82 | CYP1A2 (0.50) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5668242 | 0.80 | CACNA1G (0.51) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4390910 | 0.77 | MAPT (0.61) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2171264 | 0.77 | NPC1 (0.55) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2210734 | 0.77 | MAPT (0.31) | MAPTHTTNPSR1 | |
| SCHEMBL2172030 | 0.75 | MAPT (0.51) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5667911 | 0.75 | CYP1A2 (0.43) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2176692 | 0.74 | MAPT (0.52) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | MAPT 4524/4885CYP1A2 3488/4885CYP3A4 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.